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Abstract: The pregnancy-specific condition pre-eclampsia not only affects the health of mother 
and baby during pregnancy but also has long-term consequences, increasing the chances of 
cardiovascular disease in later life. It is accepted that pre-eclampsia has a placental origin, but 
the pathogenic mechanisms leading to the systemic endothelial dysfunction characteristic of 
the disorder remain to be determined. In this review we discuss some key factors regarded as 
important in the development of pre-eclampsia, including immune maladaptation, inadequate 
placentation, oxidative stress, and thrombosis. Genetic factors influence all of these proposed 
pathophysiological mechanisms. The inherited nature of pre-eclampsia has been known for 
many years, and extensive genetic studies have been undertaken in this area. Genetic research 
offers an attractive strategy for studying the pathogenesis of pre-eclampsia as it avoids the 
ethical and practical difficulties of conducting basic science research during the preclinical 
phase of pre-eclampsia when the underlying pathological changes occur. Although pharmaco-
genomic studies have not yet been conducted in pre-eclampsia, a number of studies investigating 
treatment for essential hypertension are of relevance to therapies used in pre-eclampsia. The 
 pharmacogenomics of antiplatelet agents, alpha and beta blockers, calcium channel blockers, and 
magnesium sulfate are discussed in relation to the treatment and prevention of pre-eclampsia. 
Pharmacogenomics offers the prospect of individualized patient treatment, ensuring swift intro-
duction of optimal treatment whilst minimizing the use of inappropriate or ineffective drugs, 
thereby reducing the risk of harmful effects to both mother and baby.
Keywords: pre-eclampsia, pharmacogenetics, placenta, trophoblast, genetics
Introduction
One of the major aims of the human genome project and subsequent disease initiatives 
was the discovery of new pharmaceutical targets. With the current advances in our 
understanding of genetics and the ever-improving sequencing technologies avail-
able we are now at an exciting time not just for research, but also for the translation 
of research results into potential health benefits due to the evolution of pharmaco-
genomics and the development of personalized medicine. The focus of this review is 
to provide a comprehensive overview of the genetic and pharmacogenetic aspects of 
pre-eclampsia. An in-depth review of the pathophysiology of the disorder is outside 
the scope of this review.1
Genetic involvement in the pregnancy-specific condition pre-eclampsia has long 
been recognized but determining the mode of inheritance and the genes involved 
has not been straightforward. Research is continuing to unravel the genetic compo-
nent of pre-eclampsia, aiding understanding of the pathophysiological changes that 
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occur in this disorder. The importance of these findings in 
 understanding the pathogenesis of pre-eclampsia cannot 
be overstated. The trigger for pre-eclampsia arises in the 
 placental bed early in pregnancy, at a time and location 
that precludes basic science research for ethical and prac-
tical  reasons. Molecular genetics research can therefore 
 provide clues to the primary causes of pre-eclampsia that 
are unavailable by other methods. Potential opportunities for 
pharmacogenomic interventions are considered in the light 
of evidence from other related diseases.
The impact of pre-eclampsia
Pre-eclampsia is a leading cause of maternal and  perinatal 
morbidity and mortality, affecting between 0.4% and 
2.8% of all pregnancies in developed countries and many 
more in developing countries, leading to over 8 million 
cases  worldwide per year.2 Although the definition of pre-
eclampsia focuses on the occurrence of hypertension and 
proteinuria, this is a multisystem disorder that may affect the 
brain, lungs, kidney, and liver. Not only does pre-eclampsia 
impact on maternal health but the growth and development 
of the fetus are frequently compromised, and pre-eclampsia 
has long-term impacts on the health of both the mother and 
offspring.3–5 A two-stage model for pre-eclampsia has been 
proposed.6 The first stage is reduced placental perfusion, 
 secondary to abnormal implantation and development of 
placental vasculature. The second stage is the maternal 
response to this condition, characterized by widespread 
inflammation and maternal endothelial cell dysfunction.7 
A number of pregnant women have pre-existing risk factors 
that make them more susceptible to the development of pre-
eclampsia and the other hypertensive disorders of pregnancy 
(see Table 1).
Studies examining plasma and tissue samples following 
the onset of pre-eclampsia have confirmed the presence of 
oxidative stress, and the release of endothelial proteins and 
pro-inflammatory cytokines,8 but discriminating between 
causal factors and secondary responses presents significant 
challenges. In this regard, genetic studies of pre-eclampsia 
offer an advantage in that genotype remains constant and is 
not affected by the disease process.
Genetic basis of pre-eclampsia
Genetic studies of pre-eclampsia have been confounded by 
the problem that there is currently no universally accepted 
definition of the disorder, with several internationally recog-
nized definitions available.9 The general consensus diagnosis 
of pre-eclampsia is a blood pressure of $140/90 mmHg 
 measured on at least two occasions separated by 6 hours after 
the twentieth week of pregnancy in a previously  normotensive 
woman, accompanied by significant  proteinuria (300 mg/L or 
500 mg/24 hours) in the absence of a urinary tract  infection.9 
In pre-eclampsia the elevated blood  pressure returns to 
normal 6 to 12 weeks following delivery. Pre-eclampsia 
can progress rapidly, at times without warning, to the life-
threatening convulsive condition eclampsia. Development of 
pre-eclampsia begins with a loss of vascular refractoriness 
to vasoactive agents followed by vasoconstriction, resulting 
in a decrease in intravascular volume. Fluid is then passed 
across the “leaky” capillaries to the extravascular space. 
Pre-eclampsia is subsequently characterized by a generalized 
dysfunction of the maternal endothelium10 with impairment 
of endothelium-dependent relaxation in maternal resistance 
arteries.11
A genetic component for pre-eclampsia has been indi-
cated since the observation in the nineteeth century of a 
clustering of cases within families.12 Challenges to defining 
this genetic involvement include the fact that the phenotype 
is expressed only in parous females, and also the need to 
evaluate the genotypes of both the mother and her fetus.
Pre-eclampsia is a complex  
genetic disorder
It is now accepted that pre-eclampsia is a complex genetic 
disorder, occurring as the result of variants at different 
loci, which individually have small effects but collectively 
contribute to an individual’s susceptibility to disease. It is 
Table 1 Risk factors for pre-eclampsia
Risk factors for pre-eclampsia
immunological Nulliparity
Primipaternity
Donor sperm/oocyte
Obstetric in vitro fertilization treatment
Multiple pregnancy
Previous adverse obstetric  
history – gestational hypertension, 
pre-eclampsia, fetal growth restriction, 
abruption placentae, perinatal death
Pre-existing conditions Chronic hypertension
Renal disease
Type 2 diabetes
Thrombophilia syndromes
Autoimmune disorder
Abnormal uterine Doppler Resistance index 0.58
Presence of diastolic notch
Maternal factors Extremes of maternal age
Black ethnicity
Obesity
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 probable that no  single gene or variant will be identified that is 
 responsible for all cases of pre-eclampsia, although different 
variants may prove to be associated with subsets of disease, 
such as early onset pre-eclampsia with fetal growth  restriction. 
In agreement with this is the recent study that identi-
f ies three separate subgroups of pre-eclampsia based 
on expression of plasma membrane proteins involved 
in angiogenesis (group 1),  mitogen-activated protein 
kinase signaling (group 2), and hormone biosynthesis 
and metabolism (group 3).13  Environmental factors, such 
as  psychological stress14 and vitamin D deficiency,15 also 
modify an individual’s risk of developing pre-eclampsia, 
determining whether variants with low penetrance result in 
phenotypic manifestation of the disease.
Deciphering the relative contribution 
of fetal and maternal genes
Investigation of both fetal and maternal genotypes is essential 
to better our understanding of the genetics of pre-eclampsia. 
An undisputable role of the placenta in the primary pathogen-
esis of pre-eclampsia is clear, indicating a fetal contribution 
to susceptibility to the disorder.16 Placental development in 
pre-eclampsia is superficial. Normal placental development 
is characterized by invasion of cytotrophoblast cells into 
the maternal decidua and inner third of the myometrium. 
Cytotrophoblast invasion serves to anchor the placenta to 
the wall of the uterus and also to gain access to the maternal 
vasculature. Endovascular trophoblast invasion enables the 
onset of placental circulation. The endovascular tropho-
blast cells also serve to trigger the process of physiologic 
conversion which is characterized by a loss of elastic fibers 
and smooth muscle cells due to proteolytic activity of the 
invasive endovascular trophoblast cells. Furthermore, spiral 
artery walls are replaced by intramural fibrin and fibrinoid, 
which is produced by the trophoblast cells, resulting in a 
considerable increase in the luminal diameter. These changes 
serve to transform the originally flexible vessels into rigid 
high-capacitance vessels which are incapable of  constricting. 
Both extravillous and endovascular cytotrophoblast inva-
sion is deficient in pre-eclampsia resulting in spiral arteries 
retaining their original architecture which precludes an 
adequate vascular response to the demands from the fetus 
for increased blood flow.17 Decreased expression of laminin 
receptor 1 by cytotrophoblasts and syncytiotrophoblasts has 
been found in pre-eclampsia which may have a role in the 
shallow trophoblastic invasion in pre-eclampsia.18 A role 
for paternally inherited fetal genes in the determination of 
clinical phenotype is evident from reports of higher rates of 
pre-eclampsia in pregnancies fathered by men who were born 
of a pre-eclamptic pregnancy.16,19
It has been suggested that an excessive or atypical 
maternal immune response to invading trophoblast may be 
the cause of the placental stage of pre-eclampsia, resulting 
in impaired decidualization and placentation. Thus, pre-
eclampsia can be considered a disease of failed interaction 
between two genetically different organisms. The genetic 
conflict hypothesis states that the fetal genetic component 
comprised of paternal genes functions to enhance the growth 
and development of the fetus by maximizing nutrient transfer 
to the fetus. In conflict with this, the maternal genes function 
to limit transfer to the fetus to ensure that no compromise is 
made to maternal health.20 Fetal genes are predicted to raise 
maternal blood pressure in order to enhance uteroplacental 
blood flow, whereas maternal genes act to oppose this. 
Endothelial dysfunction in pre-eclamptic mothers could, 
therefore, be interpreted as a fetal attempt to compensate for 
an inadequate uteroplacental nutrient supply by increasing 
maternal blood pressure. The Genetics of Pre-eclampsia 
consortium highlighted the need for examination of both 
maternal and fetal genotypes performing transmission of 
disequilibrium testing in both maternal and fetal triads.21 
Interpreting the relative contribution and interactive effects 
of both maternal and fetal genes on pre-eclampsia has not 
been straightforward, but statistical methods are now becom-
ing available.22 Unraveling the maternal and fetal genetic 
contributions to pre-eclampsia will require very large sample 
sizes, with the development of new statistical algorithms to 
aid with data analysis, including a multinomial modeling 
approach that allows the estimation of such genetic effects 
using either case/mother duos or case/parent trios.23
Candidate gene studies  
of pre-eclampsia
Over 70 candidate genes selected on the basis of prior 
biological knowledge of the pathological changes in pre-
eclampsia have been investigated. Candidate genes studied 
to date can be separated into groups based on their sug-
gested  pathophysiological mechanisms: vasoactive proteins, 
thrombophilia and hypofibrinolysis, oxidative stress and 
lipid metabolism, endothelial injury, and  immunogenetics 
(see Table 2).24 In spite of the large research effort, no 
candidate gene has been universally accepted as a causal 
gene for pre-eclampsia. Whilst this may be due in part to 
ethnic variations within study populations and inconsistency 
in the definition of  pre-eclampsia, the major reason is the 
fact that the majority of candidate gene studies have been 
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Table 2 Candidate genes and predominant polymorphisms implicated in the pathogenesis of pre-eclampsia
Proposed mechanism Gene name Gene symbol Polymorphism
vasoactive proteins Angiotensinogen AGT 235Met . Thr
Angiotensin converting enzyme ACE i/D intron 16
Thrombophilia and hypofibrinolysis Factor v Leiden F5 506Gln . Arg
Methylenetetrahydrofolate reductase MTHFR C667T
Prothrombin F2 G20210A
Plasminogen activator factor-1 SERPINE1 Promoter insertion/deletion
integrin glycoprotein iiia GPIIIA C98T
Oxidative stress and lipid metabolism Apolipoprotein E APOE C886T
Microsomal epoxide hydrolase EPHX 113Tyr . His
Glutathione-S-transferase GST A313G
Endothelial function Endothelial nitric oxide synthase 3 eNOS3 298Glu . Asp
vascular endothelial growth factor receptor 1 VEGFR1 TG repeat
vascular endothelial growth factor VEGF C936T
immunogenetics Tumour necrosis factor α TNF G-308A
interleukin 10 IL10 G1082A
grossly underpowered to detect variants with small effects. 
It is only in recent years that the small effect size of causal 
variants has become appreciated in the study of complex 
genetic disorders, with the majority of variants increasing 
disease risk by ,50%. Candidate gene studies are further 
limited by their reliance on our incomplete understanding of 
the pathogenic processes that occur in pre-eclampsia, which 
therefore restricts the genes that are evaluated.
Clotting cascade abnormalities
The occurrence of thrombophilias is well documented in 
women with pre-eclampsia.25 Establishment of the utero-
placental circulation is crucial in determining the success of 
pregnancy. Thrombophilias are believed to heighten the risk 
of placental insufficiency due to the formation of placental 
thrombi, in addition to having direct effects on trophoblast 
growth and differentiation.26 Whether the procoagulant 
state which characterizes pre-eclampsia is present before a 
pre-eclamptic pregnancy or whether it is rather a result of 
damage initiated during placentation remains unclear. The 
thrombophilic factors methylenetetrahydrofolate reductase, 
factor V Leiden variant, and prothrombin have been investi-
gated in numerous candidate gene studies. These have yielded 
conflicting results with the majority of studies showing no 
association with pre-eclampsia,24,27,28 which have been further 
confirmed by two large meta-analyses.29,30
Regulation of endothelial function 
and hemodynamics
Due to the role of the renin-angiotensin system in regu-
lating the renal and cardiovascular changes that occur 
during pregnancy this system has been implicated in the 
pathophysiology of pre-eclampsia. A number of candidate 
gene studies, concentrating mainly on angiotensin con-
verting enzyme (ACE), angiotensin II type 1 and type 2 
receptor, and angiotensinogen, have yielded inconclusive 
results. Meta-analyses have implicated the T allele of angio-
tensinogen M235T and the deletion allele of the ACE I/D 
polymorphism.31,32
Endothelial nitric oxide synthase 3 has decreased 
 activity in pre-eclampsia.33 This enzyme is important for the 
production of nitric oxide (NO), an important regulator of 
vasodilatation and vascular remodeling. Genetic association 
studies of endothelial nitric oxide synthase 3 variants in dif-
ferent ethnic populations have produced conflicting results, 
and a recent meta-analysis has shown no association with 
pre-eclampsia.31
Vascular endothelial growth factor (VEGF) has also 
been implicated in the pathophysiological changes of 
pre-eclampsia due to its role in regulating endothelial cell 
function and vascular permeability. Two small studies have 
suggested that the VEGF 405G . C and 936C . T alleles 
are associated with pre-eclampsia; results await confirmation 
in larger studies.34 The soluble fms-like tyrosine kinase 1 
(sFLT1) located on 13q12, binds VEGF with high affinity 
thus preventing VEGF from interacting with its receptor 
VEGFR1, resulting in decreased bioavailability of VEGF. 
The incidence of trisomy 13 is 2.3 in 10,000 births in 
pregnancies with pre-eclampsia in comparison with 0.5 in 
10,000 births in pregnancies without pre-eclampsia.35 It is 
suggested that the extra copy of chromosome 13 in trisomy 
13 results in increased levels of sFLT1, explaining the 
increased incidence of pre-eclampsia in women carrying 
trisomy 13 conceptuses.36
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Oxidative stress and lipid 
metabolism
Oxidative stress is central to the pathogenesis of pre-
 eclampsia.37 During the first trimester of pregnancy placental 
development is in relatively hypoxic conditions, thereby pro-
tecting fetal DNA from the harmful effects of damaging free 
radicals.38 Between gestational weeks 8 and 12  extravillous 
trophoblast plugs are released allowing maternal perfusion 
of the placenta.39 This leads to a sudden burst of oxidative 
stress. In normal pregnancy oxidative damage is prevented 
by the expression of antioxidant enzymes including gluta-
thione peroxidase, catalase, and various forms of superoxide 
dismutase.40,41 Expression of these antioxidant enzymes is 
reduced in the pre-eclamptic placenta leading to a cascade of 
events which result in impaired placental development. The 
reduced antioxidant protection in pre-eclampsia culminates 
in inadequate inactivation of harmful reactive oxygen species 
(ROS) which cause endothelial dysfunction through lipid 
peroxidation.42 Only a small number of genes involved in regu-
lating oxidative stress have been examined in pre-eclampsia, 
including epoxide hydrolase and glutathione-S-transferase, and 
none has been clearly shown to increase susceptibility.43–45
Abnormal lipid profiles are a characteristic feature of 
pre-eclampsia, including the increase in lipid peroxidation 
brought about by increased oxidative stress. Two major regu-
lators of lipid metabolism, lipoprotein lipase (LPL) and apoli-
poprotein, are abundantly expressed in the  placenta and have 
been investigated as candidate genes for  pre-eclampsia.46–48 
The Asn291Ser mis-sense mutation in LPL has been asso-
ciated with lowered plasma LPL activity and increased 
dyslipidemia in pre-eclampsia,47 but other researchers have 
failed to confirm these findings.49
Immune system involvement  
in pre-eclampsia
The fetus is hemiallogeneic with respect to its mother, and 
the maternal immune response is a key factor in determining 
pregnancy outcome. The increased risk of pre-eclampsia in 
first pregnancies suggests immune system involvement in 
its pathogenesis. A lengthy period of exposure to paternal 
semen prior to pregnancy appears to be protective, which may 
explain in part the three-fold increase in risk of developing 
pre-eclampsia following use of donor sperm or oocytes.50,51
Killer immunoglobulin-like receptors  
and the human leucocyte antigen
Expression of major histocompatibility complex molecules 
by invading extravillous cytotrophoblast cells is limited to 
the invariant Class 1b molecules, human leucocyte antigen 
(HLA)-E, HLA-F, and HLA-G, and the moderately polymor-
phic Class Ia antigen HLA-C. Interactions between tropho-
blast HLA-C and maternal killer-cell immunoglobulin-like 
receptors (KIR) expressed by uterine natural killer cells are 
important for regulating trophoblast invasion and are crucial 
for successful placentation.52 The two basic KIR haplotypes, 
A and B, differ in that the B haplotype is more potent in 
activating uterine natural killer cells, and stimulating the 
secretion of cytokines essential for trophoblast invasion. 
Fetal HLA-C antigens are also represented by two groups, 
HLA-C1 and HLA-C2, which have differing affinities for 
KIR haplotypes. There is evidence that certain maternal KIR/
fetal HLA-C combinations increase the risk of inefficient 
placentation leading to pre-eclampsia.53
TNFα
Excessive release of tumor necrosis factor alpha (TNFα) is 
associated with endothelial activation, and plasma levels of 
TNFα are significantly higher in women with pre- eclampsia.54 
Furthermore, treatment of pregnant rats with TNFα induces 
hypertension.55 TNFα is also involved in the production of 
ROS and oxidant-mediated endothelial damage. The most 
frequently studied polymorphism in the TNFα gene is the 
308G . A transition in the promoter region, which is asso-
ciated with increased production of TNFα. This variant has 
been associated with an increased risk of pre-eclampsia and 
pre-eclampsia linked disorders, including type 2  diabetes, 
coronary artery disease, and dyslipidemia.56,57 However, a 
large-scale meta-analysis of this polymorphism failed to 
demonstrate significant association with pre-eclampsia.58
interleukin 10 (iL-10)
Trophoblast invasion and spiral artery remodeling are also 
regulated by IL-1059 which is expressed at lower levels in 
pre-eclamptic placentae compared to matched controls.60 
Large-scale studies examining genetic variants of IL-10 
have failed to demonstrate a significant association with 
pre-eclampsia.61,62
Animal models of pre-eclampsia
Due to the differences in placental development between 
humans and other mammals, specifically deep trophoblast 
invasion, animal models have been of only limited sig-
nificance in the help to elucidate factors involved in the 
pathophysiology of pre-eclampsia.63 However, recently the 
murine catechol-O-methyltransferase (COMT) knockout 
model has been useful in unraveling the significance of 
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decreased placental COMT expression in pre-eclampsia. 
Estradiol is metabolized by cytochrome P450 generating 
17-hydroxyestradiol which is a substrate for COMT, which 
converts 17-hydroxyestradiol into 2-methoxyestradiol 
(2-ME). 2-ME inhibits HIF-1α by possibly destabiliz-
ing microtubules in trophoblasts.64 During pregnancy the 
concentration of maternal circulatory 2-ME immediately 
increases and peaks at term.64,65 The plasma concentration of 
2-ME is decreased in pre-eclampsia.64 COMT-deficient mice 
(COMT-/-) display a pre-eclampsia-like phenotype, includ-
ing pregnancy-induced hypertension with  proteinuria.64 
Administration of exogenous 2-ME ameliorates the hyper-
tension, proteinuria, placental defects, acute atherosis, and 
glomerular and placental endothelial damage present in 
pregnant COMT-/- mice. It is thought that the pre-eclampsia 
like symptoms present in COMT-/- mice is due to placen-
tal accumulation of HIF-1α. In the presence of COMT, 
2-ME suppresses HIF-1α accumulation and production of 
sFLT1. In COMT-/- mice, however, HIF-1α accumulation 
is associated with an increased inflammatory response and 
endothelial damage.
The rs4680 polymorphism in the coding sequence of 
COMT produces a G to A nucleotide substitution leading to 
a valine to methionine amino acid substitution at amino acid 
position 158.66 The COMT Met158 variant has a lower stability 
and shows a lower enzymatic activity, with this variant pres-
ent in around 30% of the population. This polymorphism has 
been found to be associated with fetal growth restriction and 
abnormalities.66 Pre-eclampsia may therefore be associated 
with such polymorphisms within the COMT gene, however, 
robust genetic studies are still needed to confirm or dispute 
such an association.
Genome-wide screening
Genome-wide screening provides an unbiased approach to the 
search for susceptibility genes for pre-eclampsia, unlimited 
by current understanding of the underlying pathophysiologi-
cal changes. It therefore offers an opportunity to elucidate 
previously unsuspected pathogenic pathways, and identify 
novel interventional targets.
Genome-wide linkage screens (GWLS)
GWLS have been very successful in identifying highly 
penetrant variants in monogenic disorders, but this method 
is inadequately powered for detecting the causal variants 
with small effect size typical of complex genetic disorders. 
A number of GWLS have been performed in pre-eclampsia, 
assessing the segregation of microsatellite alleles in affected 
siblings. This method can only identify relatively large 
regions of the genome, typically tens of centimorgan in size, 
and containing hundreds of genes, many of which may be bio-
logically plausible. Significant linkage with pre-eclampsia on 
chromosomes 2p13,67 2p25,68 and 9p1368 has been reported. 
Suggestive linkage has also been described at different loci on 
chromosomes 2q, 9p, 10q, 11q, and 22q.69,70  Disappointingly, 
none of these loci have been independently replicated in 
another GWLS. Limited statistical power is a major factor 
in the failure to replicate these GWLS in studies of complex 
genetic disorders. Meta-analysis of the five GWLS performed 
in pre-eclampsia produced modest evidence for linkage at 
several loci, but cautioned that insufficient data were avail-
able for conclusive results.71
Positional candidate genes
Activin A receptor type IIA (ACVR2A) has been identified 
as a strong positional candidate on the 2q22-23 locus. As 
a key receptor for the cell-signaling protein activin A, an 
important regulator of human pregnancy, ACVR2A represents 
a biologically plausible candidate. Activin A has also been 
investigated as a potential biomarker for pre-eclampsia as 
circulating levels are increased in pre-eclamptic  pregnancies.72 
In a large study of over 1100 pre-eclamptic women and 
2200 normotensive controls, four single nucleotide poly-
morphisms (SNPs) in ACVR2A were significantly associated 
with pre-eclampsia,73 and the influence of these variants on 
the expression and function of ACVR2A is currently being 
investigated. However, in a study of 74 affected families from 
Australia/New Zealand the ACVR2A association was not 
replicated.74 This gene still remains an interesting target due 
to its strong biological involvement in the establishment and 
maintenance of pregnancy.
Within the pre-eclampsia linkage peak on chromosome 
2p25 lies the ROCK2 gene. This gene encodes rho-associated 
coiled-coil protein kinase 2 and, interestingly, has been 
implicated in essential hypertension.68 ROCK2 is widely 
expressed in smooth muscle cells and animal models have 
indicated a role in vasoconstriction.75,76 It has also been 
shown that syncytiotrophoblast cells of the placenta express 
ROCK2 and expression is up regulated in pre-eclampsia.77 
A study examining ten polymorphisms within ROCK2 failed 
to detect any association with pre-eclampsia.78 This study was 
powered only to detect a genetic effect of 1.6, and a larger 
study is warranted to investigate both ROCK2 and other 
genes at the 2p25 locus.
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Genome-wide association  
screening (GWAS)
GWAS is a second unbiased approach to the identification of 
susceptibility genes for pre-eclampsia. Rather than sequenc-
ing the entire genome GWAS makes use of the abundant 
SNPs scattered throughout the human genome. Due to the 
lack of independence between the alleles of SNPs in close 
proximity, a phenomenon known as linkage disequilibrium, 
a number of representative tagSNPs can be used to infer the 
genotype of adjacent SNPs. Genotyping of between 300,000 
and 1 million carefully selected tagSNPs enables the majority 
of variation in the human genome to be captured. A SNP that 
is associated with disease may be causal, or may be acting as a 
marker for another functional SNP in linkage  disequilibrium. 
Deep resequencing is often required to identify all the poly-
morphisms present at the susceptibility locus.
GWAS has identified over 2000 genetic variants associated 
with common diseases, including essential hypertension, coro-
nary artery disease, and type 2 diabetes79 conditions which carry 
an increased risk of pre-eclampsia. Although many of these loci 
have been independently confirmed, further functional studies 
are frequently required in order to elucidate the exact pathophys-
iological mechanisms involved in these disease  processes. 
GWAS to identify susceptibility genes for pre-eclampsia are 
currently underway; the results are eagerly awaited.
Treatment and prevention  
of pre-eclampsia
Prevention, early identification, and individualized treat-
ments may become feasible if reliable early biomarkers 
can be developed. A recent microarray study has found 
dysregulation of gene expression in early placenta in women 
6 months before development of pre-eclampsia,80 confirming 
placental involvement in this disorder, and also offering the 
prospect of early prediction of those women at highest risk. 
It is hoped that completion of GWAS studies and subsequent 
deep resequencing will help suggest additional biomarkers 
and improve our understanding of the pathophysiological 
changes that occur in this disorder.
A number of interventions are available to help treat and 
prevent pre-eclampsia, including antiplatelet agents, beta 
blockers, alpha blockers, diuretics, vasodilators (NO agents), 
and calcium channel blockers.81
The benefits of pharmacogenomics
The aim of pharmacogenomics is to individualize treat-
ments in a rational and directed manner, thereby removing 
the  element of trial and error from current clinical practice. 
This will in turn reduce morbidity and mortality at the same 
time as maximizing the benefit to patients and significantly 
reducing costs. In the UK, around 6.5% of hospitalizations are 
due to adverse drug reactions.82 The benefits of personaliza-
tion and rationalization of treatment by pharmacogenomic 
approaches are therefore clear. They would be of particular 
benefit for treatment of pre-eclampsia, a condition in which 
patients can deteriorate rapidly and therefore need treatments 
that are immediately effective.
Oncology is the current leading example for personalized 
medicine with pharmacogenomics being used to identify new 
targets influencing drug absorption, distribution, metabolism 
and excretion, drug safety, and drug efficacy. The ability to 
segregate patients into drug responders and nonresponders is 
the cornerstone of personalized medicine and is now becoming 
standard practice in the use of oncology  medication. Genetic 
prediction of adverse effects is one of the major successes of 
pharmacogenomics, for example, prediction of hypersensitiv-
ity to the antiretroviral drug abacavir used to treat patients 
infected with human immunodeficiency virus.83,84
A clear message coming from researchers interested 
in pharmacogenomics and personalized medicine is that 
translation of this research into clinical benefit demands 
access to large, well-characterized sample bio banks. 
This will require large-scale international collaborations, 
exemplified by the International Warfarin Pharmacogenet-
ics Consortium which has identified a model comprising 
environmental factors (age, height, weight, and amiodarone 
use) and genotype at rs9923231 (VKORC1), rs1799853 
and rs1057910 (CYP2C9*2 and *3), rs2108622 (CYP4F2), 
and rs6042 (F7), which accounts for over 50% of warfarin 
stable dose variance.85 Sharing of knowledge has been 
facilitated by the development of databases, such as the 
Pharmacogenomics Knowledge Base (PharmGkb),86 to act 
as worldwide resources.
The ever-increasing level of data being generated about 
our genomes and health and disease is leading the way for so-
called proactive P4 (prediction, personalization, prevention, 
participation) medicine. P4 medicine is important for future 
health as it will enable the prediction of individual health risk 
and also allow the development of personalized treatment 
based on an individual’s genetic variation. Furthermore, 
P4 medicine will lead to the prevention of more disease by 
the design of new therapeutic drugs. However, for P4 medi-
cine to be fully beneficial patients, doctors and the medical 
community must all understand and participate.87
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Drug metabolism is the key  
to pharmacogenomics
The challenge within pharmacogenomics is to define the 
physiological pathways that are involved in drug metabolism; 
pathways which involve multiple interacting proteins. Each 
of these proteins may contain a polymorphism, transcrip-
tion of these proteins is in turn regulated by proteins, which 
again may contain polymorphisms in their genetic coding. 
Further complexity is added as these biochemical pathways 
can interact amongst themselves in complex ways which 
are as yet undefined. This can make determining the actual 
cause of a change to a response to a drug very difficult. Such 
complexity has led to two generic streams for pharmaco-
genomic research: studies based on the pathophysiological 
pathways involved in disease and studies based on genome-
wide association screening.
Nitric oxide synthase as a potential 
target for therapy for pre-eclampsia
Endothelial dysfunction is characteristic of pre-eclampsia, 
being associated with the hypertension and proteinuria that 
are symptomatic of this disorder. Among several mediators 
released by the endothelium, NO plays an important role in 
regulating endothelial function (see Figure 1). NO produced 
by the endothelium targets the vascular smooth muscle, 
and activates soluble guanylate cyclase by interacting with 
its heme group. This enzyme synthesizes cyclic guanosine 
monophosphate from guanosine triphosphate, leading to 
an accumulation of cyclic guanosine monophosphate. This 
activates intracellular signaling pathways that decrease 
the degree of vascular smooth muscle contraction leading 
to vessel relaxation.88 In addition to functioning as an 
endogenous vasodilator, NO also serves as a platelet inhibitor, 
antioxidant, and regulator of vascular endothelium by sus-
taining its anticoagulant and antithrombogenic properties,89 
all of which are perturbed in pre-eclampsia. Within the 
cardiovascular system it is the endothelial isoform of nitric 
oxide synthase (eNOS) which is responsible for NO synthe-
sis.90 Reduced expression of eNOS consequently results in 
reduced NO bioavailability which plays a significant role in 
the endothelial dysfunction associated with pre-eclampsia.91 
eNOS represents an interesting pharmacogenomic target, 
but the multiple interdependent control mechanisms and 
signaling pathways that act throughout the various stages of 
the enzyme’s life history make this a difficult challenge.
Pre-eclampsia is also associated with an increase in oxida-
tive stress. The ROS superoxide anion is able to react with 
NO resulting in the formation of the highly damaging per-
oxynitrite, and further reducing the bioavailability of NO.92 
ROS can also cause oxidation of the tetrahydrobiopterin 
cofactor of eNOS, resulting in uncoupling of this enzyme 
and further production of superoxide anion in favor of NO,93 
a vicious cycle that further increases oxidative stress.
The eNOS gene, located on 7q35-7q36, is approximately 
21 to 22 Kb and consists of 26 exons and 25 introns.94,95 
Since its characterization in the 1990s, a large number of 
polymorphic sites have been identified in the eNOS gene, 
including variable number tandem repeats, dinucleotide 
repeats (CA)n, and SNPs. Several polymorphisms have 
been associated with pre-eclampsia and other  cardiovascular 
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Figure 1 The importance of nitric oxide (NO) in the regulation of endothelial function.
Abbreviations: eNOS, endothelial nitric oxide synthase; BH4, tetrahydrobiopterin; GC, guanylate cyclase; GTP, guanosine triphosphate; cGMP, cyclic guanosine 
monophosphate; ONOO-, peroxynitrite; OH, hydroxide.
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and hypertensive disorders.96–98 A relationship between eNOS 
polymorphisms and differential responses to several classes 
of cardiovascular drugs has been shown,99 some of which are 
used for the treatment of  pre-eclampsia.
In animal models statins have been shown to be beneficial 
in ameliorating pre-eclampsia100 and currently the StAmP 
(Trial of provaStatin to Ameliorate early onset Pre-eclampsia) 
trial is underway to assess the use of statins in pregnancy as 
a therapeutic intervention to prolong pre-eclamptic pregnan-
cies, thereby reducing the incidence of prematurity associ-
ated with the disorder.101 Recent evidence suggests genetic 
polymorphisms of eNOS modulate the effects of statins. 
Statin treatment induced a greater increase in eNOS mRNA 
levels in cultured endothelial cells with the CC genotype at 
the -786T . C polymorphism compared to cells with the TT 
genotype.102 These findings have been confirmed in a clinical 
study showing that atorvastatin increases the bioavailability 
of NO and decreases oxidative stress in CC homozygotes.103 
The same polymorphism in the eNOS gene modulates the 
anti-inflammatory effect of atorvastatin, resulting in sig-
nificant reductions in the inflammatory cytokines CD40L, 
VCAM-1, P-Selectin, and MMP-9 in individuals with the 
CC genotype but not the TT genotype.104 These findings 
suggest that statins might be more useful for the treatment 
of pre-eclampsia in women with the CC genotype than in 
those with the TT genotype.
A further polymorphism in intron 4 (4a/b) of the eNOS 
gene is also associated with modulation of the response 
to statins. In a study evaluating coronary vasodilatation 
induced by adenosine after 6-months’ treatment with pravas-
tatin, individuals carrying an A allele showed significant 
improvement of vasodilatation compared to homozygous 
bb individuals, possibly due to increased endothelial pro-
duction of NO.105
Prevention of pre-eclampsia
Labetalol
Labetalol is a mixed alpha- and beta-blocker that is used 
for controlling high blood pressure during pregnancy. 
Although no studies have been performed examining phar-
macogenomic effects on labetalol, a number of studies have 
been performed assessing other beta-blockers in patients 
with hypertension which may be of relevance to the use 
of labetalol in pre-eclampsia. Using a technique similar to 
GWAS, polymorphisms in eNOS have been shown to be 
associated with variations in pharmacological responses to 
the beta-blocker atenolol. In hypertensive patients, allele G 
of the A2996G polymorphism in eNOS is associated with a 
greater decrease in blood pressure following treatment with 
atenolol compared with patients with the A allele.106 Allele A 
of the G498A polymorphism in the eNOS gene is also asso-
ciated with a better response to atenolol treatment.106 The 
presence of a 2996G allele and a 498A allele may therefore 
be beneficial for patients treated with beta-blockers. These 
promising results need to be confirmed in a higher number 
of patients from different populations but may be important 
when considering pharmacogenomic approaches to the treat-
ment of pre-eclampsia.
Hydralazine (HDZ)
HDZ is commonly used in pre-eclampsia as an intravenous 
treatment for quickly lowering severely high blood pressure 
during pregnancy.107 Hypotension is a frequent adverse 
effect of HDZ treatment.107 HDZ is biotransformed by the 
enzyme N-acetyltransferase (NAT) forming acetyl HDA, 
which spontaneously converts to the stable product 3- met
hyl-S-triazolo-[3,4-a]-phthalazine.108 Two isoforms of NAT 
are encoded by NAT1 and NAT2. Several polymorphisms 
in NAT1 and NAT2 have functional consequences including 
truncation of the proteins, which leads to reduced enzyme 
activity. This affects the rates of inactivation of many drugs, 
including HDZ.109
As previously mentioned, COMT deficiency is implicated 
in the pathogenesis of pre-eclampsia. Importantly, HDZ 
has also been shown to inhibit placental COMT activity.110 
Therefore, HDZ mediated suppression of COMT/2-ME needs 
to be carefully evaluated for its connection with possible 
drug-exacerbated pre-eclampsia.
However, it is questionable whether pretreatment NAT 
genotyping would be clinically justified, as the benefits of 
HDZ therapy in severe pre-eclampsia outweigh the risk of 
adverse drug reactions.
Aspirin
Aspirin reduces the risk of pre-eclampsia111 through its 
antithrombotic action. A recent Cochrane review showed 
that aspirin at doses of between 50 and 150 mg/day reduces 
the risk of pre-eclampsia by 17% (relative risk 0.83; 95% 
confidence interval 0.77–0.89).112 Current guidelines from 
the National Institute for Health and Clinical Excellence81 
recommend that women at high risk of pre-eclampsia should 
take aspirin 75 mg daily from 12 weeks of pregnancy until 
the birth of the baby. Low-dose aspirin functions as an 
antiplatelet agent through its ability to irreversibly acetylate 
and thus inhibit the enzyme cyclo-oxygenase-1 (COX-1). 
This suppresses the synthesis of thromboxane A
2
, a potent 
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vasoconstrictor and activator of platelet aggregation.112 
Therefore, low-dose aspirin may enhance uterine blood 
flow and tissue perfusion, and promote optimal uterine 
hemodynamics.
There is interindividual variation in the antiplatelet effects 
of aspirin giving rise to the concept of antiplatelet drug 
resistance.113 A number of laboratory assays are available to 
test for aspirin resistance which include light transmission 
aggregometry, platelet function analyser-100,  VerifyNow® 
Aspirin system (Accumetrics, San Diego, CA), thromboelas-
tography, or measurements of serum levels of thromboxane B
2
 
or the urinary metabolite 11-dehydro-thromboxane B
2
. The 
definition of antiplatelet drug resistance is controversial and 
therefore the reported prevalence varies widely, between 5% 
and 60%, depending on the laboratory methods used and 
the population studied.114–116 However, it is important to note 
that poor compliance by patients has been identified as a 
primary cause of resistance.117 In addition to COX-1-specific 
effects, aspirin also has COX-1 independent effects, which 
may be subject to more interindividual variability and may 
explain the adverse outcomes among patients with high 
platelet reactivity.114,118
A number of mechanisms may be related to aspirin 
 resistance.119 Clinical factors including poor patient compli-
ance, drug-absorption abnormalities, or drug–drug interac-
tions play a role.120 Cellular factors have also been proposed 
to influence aspirin efficacy, such as inadequate suppression 
of platelet COX-1 due to increased platelet turnover, over 
expression of COX-2 mRNA, erythrocyte-platelet interac-
tion, catecholamine levels, or the generation of 8-iso-PGF
2
.121 
Polymorphisms in both the COX-1 and COX-2 genes may 
have roles in aspirin resistance.122 The COX-1 C50T and 
COX-2 (G-765C) polymorphisms have both been associated 
with the efficiency of reduction of thromboxane B
2
 levels 
after aspirin treatment.118,123
A number of polymorphisms have been identif ied 
as being associated with aspirin drug resistance (see 
Table 3).121,124 However, these studies have often been 
underpowered and inconclusive. This is perhaps not surpris-
ing given the different methods used to assess resistance 
and the lack of assessment of compliance. A comprehensive 
systematic review and meta-analysis of pharmacogenomics 
of aspirin resistance has been performed identifying 50 
polymorphisms in eleven genes in the aspirin pathway.125 
A subgroup analysis in healthy individuals identified a 
statistically significant genetic association between aspirin 
resistance and a polymorphism in the glycoprotein (GP) IIb/
IIIa platelet receptor gene. The platelet GPIIb/IIIa receptor is 
essential for platelet activation and aggregation by binding 
fibrinogen and von Willebrand factor. This receptor com-
plex is the main pharmaceutical target for aspirin and other 
antiplatelet therapies. The GP IIb/IIIa complex is highly 
polymorphic. Healthy carriers of the PIA2 allele, which is 
responsible for a Pro33 Leu amino acid change, are 2.36 
times more likely to display resistance to aspirin126 and there-
fore require a greater dose of aspirin to experience the same 
antiaggregant effect as do subjects with a PIA1 homozygous 
genotype.127 However, no studies have been undertaken in 
pregnant women on aspirin to determine whether there is 
genetic variability in response to aspirin, and certainly this 
has never been related to clinical outcomes.
A second complex which may also regulate patient response 
to aspirin and other antiplatelet agents is the GP Ia/IIa complex, 
a high-affinity receptor for collagen which plays a key role in 
platelet adhesion. Polymorphisms that alter the structure and 
density of the GP Ia/IIa receptor complex on the platelet surface 
include C807T (Phe 224), a silent polymorphism affecting the 
Ia subunit. The 807T allele is associated with up to ten times 
higher expression of the receptor on the platelet surface and 
may modify the effect of antiplatelet drugs.128
Table 3 Summary of pharmacogenomic studies on antiplatelet agents
Protein Polymorphism Patient numbers  
studied
Functional effects Clinical effects
GP iib/iiia PiA(Pro33Leu) .5000 individuals with PiA2 allele require higher dose of aspirin  
to achieve comparable anti-aggregant effect as wild-type  
homozygotes
increased risk of 
thrombosis
GPia C807T 1170 Associated with collagen-receptor density on the platelet 
membrane surface and greater platelet reactivity
Conflicting data
COX-1 C50T 563 Associated with higher levels of thromboxane B2 No clinical data
COX-2 G-765C 24 Associated with a higher reduction of thromboxane  
B2 levels after aspirin treatment
No clinical data
ADP subtype receptor P2Y12 980 Associated with reduced platelet aggregation after  
aspirin intake
No clinical data
Abbreviations: ADP, adenosine diphosphate; COX, cyclooxygenase; GP, glycoprotein.
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Magnesium sulfate
Magnesium sulfate is used therapeutically to prevent eclamp-
tic convulsions in women with pre-eclampsia. The pharmaco-
logical actions of magnesium include cerebral vasodilatation 
thereby reducing cerebral ischemia,129 or blocking of neuronal 
damage associated with ischemia.130 However, magnesium 
sulfate also has side effects for the mother.131 An increase in 
postpartum hemorrhage has been reported following mag-
nesium sulfate treatment,132 although its incidence was not 
increased in the Magpie trial.133 Importantly, magnesium is 
able to cross the placenta and hypermagnesemia in the neo-
nate is associated with flaccidity, hyporeflexia, and respira-
tory depression.134 To the best of the authors’ knowledge, 
no pharmacogenomic studies have been performed with 
magnesium sulfate.
Calcium channel blockers
The calcium channel blockers nifedpine, verapamil, and 
nicardipine are also recommended to treat hypertension 
in pre-eclampsia.135 Calcium channel blockers function 
by blocking voltage-gated calcium channels in the heart 
and vasculature, thereby reducing intracellular calcium. 
In the heart, this results in decreased cardiac contractility 
and reduced cardiac output; in the blood vessels, this leads 
to decreased smooth muscle contraction and peripheral 
 resistance. Although no pharmacogenomic studies have 
been performed in pre-eclampsia, over recent years, a num-
ber of studies have examined calcium channel blockers in 
the treatment of hypertension. Three SNPs in CACNA1A 
(rs2239050, rs2238032, and rs2239128) have been associated 
with success of treatment in a study of blood pressure lower-
ing with calcium channel blockers,136 however,  Beitelshees 
et al137 failed to replicate this finding. A recent study has also 
shown that individuals with rs1051375 A/A benefit from 
treatment with a calcium channel blocker, whereas those 
with the G/G genotype would benefit from treatment with a 
beta blocker, and in those individuals that are heterozygous 
it does not matter which treatment is chosen.137 Suggestive 
associations between CYP3A5*3 and CYP3A5*6 variants 
and verapamil treatment for blood pressure and hypertension 
risk outcomes in black and Hispanic populations have also 
been observed.138 The Glu65 Lys and Val110Leu variants 
of KCNMB1 have also been studied with regard to systolic 
blood pressure regulation by verapamil. Although blood 
pressure response did not vary by genotype, Lys65 carriers 
achieved earlier blood pressure control and required fewer 
additional  treatments. Leu110 carriers were found to have 
a reduced risk of death, myocardial infarction, or stroke.139 
Higher mortality rates have also been reported for individuals 
with the Ser49-Arg389 variant of ADRB1 following treatment 
with verapamil.140 Additionally, individuals homozygous 
for the T allele of NPPA T2238C had more favorable clini-
cal outcomes when treated with a calcium channel blocker 
whereas C carriers responded better to a diuretic.141
Conclusion
The need for collaboration within the field of genetics of pre-
eclampsia, as with all other complex genetic disorders, is now 
accepted by researchers. Only large-scale collaborations can 
achieve sufficient sample sizes to perform adequately powered 
studies. Whilst a role for pharmacogenomics is accepted in 
the field of cancer treatment, further research is needed before 
pharmacogenomic approaches can be considered appropriate 
for pre-eclampsia. Due to concerns about possible teratogenic/
harmful effects on the fetus only minimal medication is 
given to a woman during pregnancy. A recent Confidential 
Enquiry into Maternal and Child Health report, attributes the 
occurrence of fatal intracranial hemorrhages to inadequate 
treatment of severe systolic hypertension (.160 mmHg) in 
women with pre-eclampsia, recommending urgent and effec-
tive treatment for such cases.142 Pharmacogenomics could help 
reduce the incidence of such fatal hemorrhages by helping to 
ensure that women received the optimal treatment regimen for 
them. Such accurate prediction of which women will respond 
well to a particular treatment will be further beneficial in 
the management of pre-eclampsia by preventing unneces-
sary exposure of the fetus to ineffective drugs. Progress in 
understanding the genetic component of pre-eclampsia will 
aid development of novel pharmaceutical treatments; person-
alized medicine informed by pharmacogenomics will target 
the treatments for this devastating disorder of pregnancy at 
those most likely to benefit.
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